JP7330174B2 - オートファジーをモジュレーションするための方法及び医薬組成物 - Google Patents

オートファジーをモジュレーションするための方法及び医薬組成物 Download PDF

Info

Publication number
JP7330174B2
JP7330174B2 JP2020516833A JP2020516833A JP7330174B2 JP 7330174 B2 JP7330174 B2 JP 7330174B2 JP 2020516833 A JP2020516833 A JP 2020516833A JP 2020516833 A JP2020516833 A JP 2020516833A JP 7330174 B2 JP7330174 B2 JP 7330174B2
Authority
JP
Japan
Prior art keywords
dbi
antibody
autophagy
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534337A5 (https=
JP2020534337A (ja
Inventor
クレーマー，ギード
ブラボ・サン・ペドロ，ホセ・マニュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Sorbonne Universite, Universite Paris Cite filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2020534337A publication Critical patent/JP2020534337A/ja
Publication of JP2020534337A5 publication Critical patent/JP2020534337A5/ja
Application granted granted Critical
Publication of JP7330174B2 publication Critical patent/JP7330174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
JP2020516833A 2017-09-20 2018-09-19 オートファジーをモジュレーションするための方法及び医薬組成物 Active JP7330174B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306229 2017-09-20
EP17306229.0 2017-09-20
PCT/EP2018/075286 WO2019057742A1 (en) 2017-09-20 2018-09-19 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA

Publications (3)

Publication Number Publication Date
JP2020534337A JP2020534337A (ja) 2020-11-26
JP2020534337A5 JP2020534337A5 (https=) 2021-08-05
JP7330174B2 true JP7330174B2 (ja) 2023-08-21

Family

ID=60009555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516833A Active JP7330174B2 (ja) 2017-09-20 2018-09-19 オートファジーをモジュレーションするための方法及び医薬組成物

Country Status (5)

Country Link
US (5) US20200268837A1 (https=)
EP (1) EP3684471A1 (https=)
JP (1) JP7330174B2 (https=)
CN (1) CN111655340A (https=)
WO (1) WO2019057742A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4013883A1 (en) * 2019-08-16 2022-06-22 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
CN118922206A (zh) * 2022-02-08 2024-11-08 国家医疗保健研究所 乙酰辅酶a结合蛋白的中和赋予自噬依赖性器官保护
EP4309733A1 (en) * 2022-07-22 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
CN115990159B (zh) * 2023-02-16 2024-05-17 中山大学 阿曲生坦或其药学上可接收的盐在制备治疗肌肉萎缩侧索硬化症产品中的应用
EP4698185A1 (en) * 2023-04-18 2026-02-25 Osasuna Therapeutics SA Methods and systems for improving anti-cancer therapies
WO2025134073A2 (en) * 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating diseases or conditions induced by corticosteroids, synovial inflammation, and degenerative joint disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1222277A2 (en) * 1999-10-05 2002-07-17 Curagen Corporation Endozepine-like polypeptides and polynucleotides encoding same
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2758189C (en) 2009-04-10 2020-12-29 Association Institut De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2015049365A2 (en) * 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemistry and Physics of Lipids，2008年，Vol. 154S, PO109，S61
Plant Molecular Biology，1998年，Vol. 38，pp. 827-838
Progress in Lipid Research，2015年，Vol. 59，pp. 1-25

Also Published As

Publication number Publication date
US20230142694A1 (en) 2023-05-11
CN111655340A (zh) 2020-09-11
US20200268837A1 (en) 2020-08-27
WO2019057742A1 (en) 2019-03-28
EP3684471A1 (en) 2020-07-29
US20240245750A1 (en) 2024-07-25
US20260097094A1 (en) 2026-04-09
US11905330B1 (en) 2024-02-20
JP2020534337A (ja) 2020-11-26
US12343376B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
JP7330174B2 (ja) オートファジーをモジュレーションするための方法及び医薬組成物
JP7638215B2 (ja) 腎障害の治療
US20220168419A1 (en) Compositions and methods for treating autoimmune diseases and cancers
KR20220050087A (ko) 대사성 질환의 치료 및 예방
JP2013144708A (ja) 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
CA3126322A1 (en) Treatment of hepatotoxicity
US20260116986A1 (en) Epo receptor agonists and antagonists
CN119563038A (zh) 用于调节免疫应答的组合物和方法
US8128934B2 (en) Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
WO2014209947A2 (en) Methods and compositions for the inhibition of trpv4
WO2013017656A1 (en) Antagonists of ribonucleases for treating obesity
US20180134788A1 (en) Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
WO2012043747A1 (ja) グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
KR20180005149A (ko) Ｃｄ９ 항체를 유효성분으로 함유하는 세포노화 또는 노화 관련 질환 예방 또는 치료용 약학조성물
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
WO2024204685A1 (ja) 癌の治療および／または予防のための医薬組成物
WO2025134073A2 (en) Methods and compositions for treating diseases or conditions induced by corticosteroids, synovial inflammation, and degenerative joint disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230808

R150 Certificate of patent or registration of utility model

Ref document number: 7330174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150